SCHEMBL2231964

SCHEMBL2231964

CCCCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.72
MAPK1 P28482 3/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
ALDH1A1 P00352 2/20 0.71
MEN1 O00255 2/20 0.71
GMNN O75496 2/20 0.71
LMNA P02545 2/20 0.71
BLM P54132 2/20 0.71
KMT2A Q03164 2/20 0.71
NPSR1 Q6W5P4 2/20 0.71
PRKD3 O94806 1/20 0.71
PRKCG P05129 1/20 0.71
PRKCB P05771 1/20 0.71
PRKCA P17252 1/20 0.71
PRKCH P24723 1/20 0.71
AKT1 P31749 1/20 0.71
PRKCI P41743 1/20 0.71
PRKCE Q02156 1/20 0.71
PRKCQ Q04759 1/20 0.71
PRKCZ Q05513 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2230910 1.00 RECQL (0.72) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL2231689 1.00 RECQL (0.72) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL20143294 1.00 RECQL (0.72) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL2233048 0.98 ALDH1A1 (0.71) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL2230639 0.97 RECQL (0.67) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL20143295 0.91 RECQL (0.71) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL1965814 0.91 RECQL (0.71) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL6037603 0.91 MAPK1 (0.69) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
Vb-201 SCHEMBL2071110 0.90 RECQL (0.81) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1
SCHEMBL2232633 0.90 RECQL (0.81) RECQLMAPK1SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 US disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 US disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B RECQL 4132/4885MAPK1 4229/4885SMN1; SMN2 4440/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B RECQL 4132/4885MAPK1 4229/4885SMN1; SMN2 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.